Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
2.840
-0.400 (-12.35%)
At close: Dec 12, 2025, 4:00 PM EST
2.730
-0.110 (-3.87%)
After-hours: Dec 12, 2025, 7:53 PM EST
Genprex Employees
Genprex had 15 employees as of December 31, 2024. The number of employees decreased by 11 or -42.31% compared to the previous year.
Employees
15
Change (1Y)
-11
Growth (1Y)
-42.31%
Revenue / Employee
n/a
Profits / Employee
-$1,117,947
Market Cap
6.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | -11 | -42.31% |
| Dec 31, 2023 | 26 | -2 | -7.14% |
| Dec 31, 2022 | 28 | 11 | 64.71% |
| Dec 31, 2021 | 17 | 5 | 41.67% |
| Dec 31, 2020 | 12 | 4 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GNPX News
- 19 days ago - Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PRNewsWire
- 24 days ago - Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials - PRNewsWire
- 25 days ago - Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PRNewsWire
- 5 weeks ago - Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer - PRNewsWire
- 6 weeks ago - Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 6 weeks ago - Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - PRNewsWire
- 7 weeks ago - Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 7 weeks ago - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics - PRNewsWire